All Releases
Subscribe
Subscribe to Stada Arzneimittel

04.07.2019 – 10:35

Stada Arzneimittel

Press release - STADA and BioQ Pharma launch Propofusor anesthetic in Australia

One document

Press release

STADA and BioQ Pharma launch Propofusor anesthetic in Australia

- STADA Pharmaceuticals Australia launches the propofol product Propofusor on 
  the Australian market together with its manufacturer BioQ Pharma Incorporated.
- On Friday, June 28th, BioQ Pharma announced that the Australian Therapeutic 
  Goods Administration (TGA) has approved their Propofusor product.
- Carsten Cron, STADA Executive Vice President Emerging Markets: "The launch of 
  Propofusor requires a strong commercial partner to supply the hospital market.
  Therefore, we are very proud that BioQ Pharma relies on our expertise. The 
  addition of this innovative product to our portfolio will enhance STADA's 
  reputation as a provider of quality healthcare, leading to improved patient 
  outcomes." 

Sydney, July 4, 2019 - The Australian subsidiary STADA Pharmaceuticals Australia launches the propofol product Propofusor 1% on the Australian market in cooperation with the manufacturer of the anesthetic product, BioQ Pharma Incorporated. The specialty pharmaceutical company BioQ Pharma has received approval from Australian Therapeutic Goods Administration (TGA) for its Propofusor anesthetic on Friday, June 28. Propofusor is used for induction and maintenance of general anesthesia, sedation of mechanically ventilated adults in intensive care and conscious sedation during diagnostic and surgical procedures. "With an estimated 3.7 million surgical and gastrointestinal procedures annually, the demand for high-quality anesthetics in Australia is very high. It therefore requires a strong and experienced sales partner to supply hospitals with Propofusor", emphasizes Carsten Cron, Executive Vice President Emerging Markets within the STADA Group responsible for business in Australia. "Therefore, we are very proud that BioQ Pharma relies on our expertise as a commercial partner for this important market launch. The addition of this innovative product to our portfolio will enhance STADA's reputation as a provider of quality healthcare, leading to improve patient outcomes."

Using the Company's patented invenious(TM) technology, the Propofusor is a programmable, ready-to-use, single use infusion pharmaceutical product, which is pre-filled at the point of manufacture with 1% propofol, a hypnotic amnestic agent and the world's most widely used surgical sedation drug. The self-contained system provides the ability to titrate dosage, as well as bolus capabilities.

Josh Kriesel, President and CEO of BioQ Pharma, commented, "We are looking forward to launching the Propofusor in Australia in collaboration with STADA, our Australian commercial partner, in the near-term. There is a need for convenient, ready-to-use anesthetic products in hospitals, outpatient centers and clinics that could help avoid dosing errors and breaches in sterility."

About STADA Arzneimittel AG

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription Consumer Health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 130 countries. In financial year 2018, STADA achieved adjusted Group sales of Euro 2,330.8 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 503.5 million. As of December 31, 2018, STADA employed 10,416 people worldwide.

Additional information for journalists:
STADA Arzneimittel AG 
Media Relations 
Stadastrasse 2-18 
61118 Bad Vilbel - Germany 
Phone: +49 (0) 6101 603-165
Fax: +49 (0) 6101 603-215 
E-Mail: press@stada.de
Or visit us on the Internet at www.stada.com/press 

Additional information for capital market participants:
STADA Arzneimittel AG
Investor & Creditor Relations
Stadastrasse 2-18 
61118 Bad Vilbel - Germany 
Phone: +49 (0) 6101 603-4689
Fax: +49 (0) 6101 603-215 
E-mail: ir@stada.de
Or visit us on the Internet at www.stada.com/investor-relations